Trump signs executive order to accelerate psychedelic drug reviews, including ibogaine
AI summaryPresident Donald Trump has signed an executive order directing federal agencies to speed up the review of psychedelic drugs, notably ibogaine, for treating PTSD and other conditions. The order includes $50 million in new federal funding for research and has drawn both support and skepticism from experts.